AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8922008 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulized (CN) albuterol (0.3 mg/kg/hr)
Number of subjects: 70
Study 8922008 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous nebulized (CN) albuterol
Number of subjects: 70
Study 8922008 — intervention group
Group type: COMPARATOR
Intervention: Intermittent nebulized (IN) albuterol
Number of subjects: 70
Study 1515448 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 0
Study 1515448 — intervention group
Group type: COMPARATOR
Intervention: No calcium blocker
Number of subjects: 0
Study 3919415 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line anti-rheumatic drugs (e.g., gold) continuously for 12 months
Number of subjects: 84
Study 28542799 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-parametric approach for sensitivity analysis
Number of subjects: 0
Study 28542799 — intervention group
Group type: COMPARATOR
Intervention: Parametric model for observable data
Number of subjects: 0
Study 27485930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy for elderly with Type 2 diabetes and minor depression
Number of subjects: 0
Study 24810476 — intervention group
Group type: EXPERIMENTAL
Intervention: Taikong Yangxin Prescription (TYP)
Number of subjects: 14
Study 24810476 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 14
Study 22469606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting instruments
Number of subjects: 100
Study 22469606 — intervention group
Group type: COMPARATOR
Intervention: Non-cutting instruments
Number of subjects: 100
Study 19955769 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold-blood cardioplegia enriched with N-acetylcysteine (NAC) (50 mg/kg)
Number of subjects: 44
Study 19955769 — intervention group
Group type: COMPARATOR
Intervention: Cold-blood cardioplegia alone
Number of subjects: 44
Study 18703004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 27 mg
Number of subjects: 249
Study 18703004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg q8w
Number of subjects: 249
Study 18703004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Number of subjects: 249
Study 18703004 — intervention group
Group type: EXPERIMENTAL
Intervention: Ustekinumab 180 mg
Number of subjects: 249
Study 18703004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 249
Study 15958000 — intervention group
Group type: COMPARATOR
Intervention: Traditional hysteroscopy
Number of subjects: 120
Study 15958000 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch hysteroscopy with 2.9-mm hysteroscope
Number of subjects: 120
Study 15958000 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch hysteroscopy with 4-mm hysteroscope
Number of subjects: 120
Study 15958000 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch hysteroscopy
Number of subjects: 120
Study 15958000 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 120
Study 14768951 — intervention group
Group type: EXPERIMENTAL
Intervention: small cupola held by two pins
Number of subjects: 37
Study 14768951 — intervention group
Group type: EXPERIMENTAL
Intervention: large cupola held by one pin
Number of subjects: 37
Study 14768951 — intervention group
Group type: EXPERIMENTAL
Intervention: similar cupola held by a different pin
Number of subjects: 37
Study 10941962 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental formula (supplemented with arachidonic acid and docosahexaenoic acid)
Number of subjects: 288
Study 10941962 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 288
Study 10941962 — intervention group
Group type: COMPARATOR
Intervention: Control formula (unsupplemented)
Number of subjects: 288
Study 10941962 — intervention group
Group type: EXPERIMENTAL
Intervention: All feeding groups
Number of subjects: 288
Study 8832600 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 20-micrograms doses at 0, 1, and 2 months (group II)
Number of subjects: 42
Study 8832600 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 20-micrograms doses at 0, 1, and 6 months (group III)
Number of subjects: 42
Study 8832600 — intervention group
Group type: COMPARATOR
Intervention: Single dose schedule of three 10-micrograms doses at 0, 1, and 2 months (group I)
Number of subjects: 42
Study 1596903 — intervention group
Group type: EXPERIMENTAL
Intervention: X-irradiated autologous tumor cells and Bacillus Calmette-Guérin
Number of subjects: 0
Study 1596903 — intervention group
Group type: EXPERIMENTAL
Intervention: X-irradiated autologous tumor cells mixed with gamma-interferon
Number of subjects: 0
Study 1596903 — intervention group
Group type: COMPARATOR
Intervention: Control patients (not treated with the autologous colon tumor vaccine)
Number of subjects: 0
Study 6379274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone eye drops
Number of subjects: 0
Study 6379274 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac eye drops
Number of subjects: 0
Study 31640670 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimistic graphic fact sheet
Number of subjects: 102
Study 31640670 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessimistic graphic fact sheet
Number of subjects: 102
Study 31640670 — intervention group
Group type: COMPARATOR
Intervention: Control group (current guidelines)
Number of subjects: 102
Study 29534699 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentir-nos Bé programme (12 two-hour sessions held once a week in groups of 12-15 people)
Number of subjects: 390
Study 29534699 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 390
Study 25292404 — intervention group
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharides (20 g daily for 30 days)
Number of subjects: 9
Study 25292404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 24874483 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane 25 mg day(-1) + Celecoxib 800 mg day(-1)
Number of subjects: 153
Study 24874483 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg day(-1)
Number of subjects: 153
Study 21897264 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-learning (SL) training using a voice feedback manikin
Number of subjects: 235
Study 21897264 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led (IL) training
Number of subjects: 235
Study 20933301 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (ADA)
Number of subjects: 270
Study 20933301 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (MTX)
Number of subjects: 270
Study 20933301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 17684989 — intervention group
Group type: EXPERIMENTAL
Intervention: Normothermal perfusion
Number of subjects: 0
Study 17684989 — intervention group
Group type: COMPARATOR
Intervention: Hypothermic perfusion
Number of subjects: 0
Study 11215733 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg [13C]urea + Ensure
Number of subjects: 354
Study 11215733 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg [13C]urea + citric acid
Number of subjects: 354
Study 11215733 — intervention group
Group type: COMPARATOR
Intervention: LARA
Number of subjects: 354
Study 11215733 — intervention group
Group type: COMPARATOR
Intervention: IRMS
Number of subjects: 354
Study 9124988 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T) administered as 30‐minute intravenous infusions 4 or 3 times a day for 3 to 13 days
Number of subjects: 40
Study 9124988 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (P/T)
Number of subjects: 40
Study 7512110 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha 2a interferon, 3 mega units sc tiw for 24 weeks
Number of subjects: 24
Study 7512110 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral scopolamine 0.15 mg
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral scopolamine 0.3 mg
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral scopolamine 0.6 mg
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral scopolamine 1.2 mg
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine
Number of subjects: 0
Study 3088662 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: All scopolamine conditions
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine and higher oral dose conditions
Number of subjects: 0
Study 3088662 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal scopolamine patch
Number of subjects: 0
Study 31366300 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine dose
Number of subjects: 0
Study 31366300 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline infarct volume
Number of subjects: 0
Study 31366300 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) <70 mmHg
Number of subjects: 0
Study 29589820 — intervention group
Group type: EXPERIMENTAL
Intervention: UC+TxtM (usual care plus twice-daily diabetes self-management text messages)
Number of subjects: 62
Study 29589820 — intervention group
Group type: COMPARATOR
Intervention: UC (usual care)
Number of subjects: 62
Study 29589820 — intervention group
Group type: EXPERIMENTAL
Intervention: UC+TxtM
Number of subjects: 62
Study 29589820 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 62
Study 27709282 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 400 mg
Number of subjects: 47
Study 27709282 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib 200 mg
Number of subjects: 47
Study 27709282 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 25752115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-7 weeks (treatment group I)
Number of subjects: 52
Study 25752115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanic injection of triamcinolone acetonide, administered 1 hour before radiotherapy, once a week for 1-12 weeks (treatment group II)
Number of subjects: 52
Study 25752115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no tympanic injection of triamcinolone acetonide)
Number of subjects: 52
Study 22471137 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-sensitive moxibustion
Number of subjects: 60
Study 22471137 — intervention group
Group type: COMPARATOR
Intervention: Conventional moxibustion
Number of subjects: 60
Study 20860505 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBV group)
Number of subjects: 321
Study 20860505 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care (control group)
Number of subjects: 321
Study 18230778 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent
Number of subjects: 2098
Study 18230778 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent
Number of subjects: 2098
Study 15817329 — intervention group
Group type: EXPERIMENTAL
Intervention: RT and adjuvant goserelin (Arm I)
Number of subjects: 977
Study 15817329 — intervention group
Group type: COMPARATOR
Intervention: RT alone followed by observation and application of goserelin at relapse (Arm II)
Number of subjects: 977
Study 14520857 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyroxine (TX) 75-150 mcg/day
Number of subjects: 118
Study 14520857 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium Iodide (PI) 200 mcg/day
Number of subjects: 118
Study 14520857 — intervention group
Group type: COMPARATOR
Intervention: Thyroxine (TX)
Number of subjects: 118
Study 14520857 — intervention group
Group type: COMPARATOR
Intervention: Potassium Iodide (PI)
Number of subjects: 118
Study 11009853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched leadership style plus enriched group dynamics
Number of subjects: 90
Study 11009853 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched group environment (irrespective of leadership style)
Number of subjects: 90
Study 11009853 — intervention group
Group type: COMPARATOR
Intervention: Bland leadership style plus bland group dynamics
Number of subjects: 90
Study 11009853 — intervention group
Group type: COMPARATOR
Intervention: Bland leadership style plus enriched group dynamics
Number of subjects: 90
Study 11009853 — intervention group
Group type: COMPARATOR
Intervention: Enriched leadership style plus bland group dynamics
Number of subjects: 90
Study 8882258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg at induction of anaesthesia, repeated 8 h later
Number of subjects: 66
Study 8882258 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo) at the same times
Number of subjects: 66
Study 8882258 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg
Number of subjects: 66
Study 8882258 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 66
Study 1813488 — intervention group
Group type: EXPERIMENTAL
Intervention: Ocutech Vision Enhancing System (VES)
Number of subjects: 55
Study 1813488 — intervention group
Group type: COMPARATOR
Intervention: Conventional Keplarian spectacle telescope systems
Number of subjects: 55
Study 31120108 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated matched saline infusion with urine output (active group)
Number of subjects: 136
Study 31120108 — intervention group
Group type: COMPARATOR
Intervention: Sham control (sham group)
Number of subjects: 136
Study 28693985 — intervention group
Group type: EXPERIMENTAL
Intervention: LNG-IUS
Number of subjects: 106
Study 28693985 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal methods
Number of subjects: 106
Study 26509681 — intervention group
Group type: EXPERIMENTAL
Intervention: Wireless patch
Number of subjects: 31
Study 26509681 — intervention group
Group type: EXPERIMENTAL
Intervention: Wired dose controller
Number of subjects: 31
Study 26509681 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 31
Study 26509681 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (Wireless patch and Wired dose controller)
Number of subjects: 31
Study 23417645 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative inpatient exercise program (twice daily exercise including stretching, core, balance, and low-intensity resistance exercises)
Number of subjects: 31
Study 23417645 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no structured exercise program)
Number of subjects: 31
Study 23417645 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative inpatient exercise program
Number of subjects: 31
Study 23417645 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 31
Study 21548214 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine Tartrate combined with Cardura
Number of subjects: 113
Study 21548214 — intervention group
Group type: COMPARATOR
Intervention: Cardura alone
Number of subjects: 113
Study 18945928 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Number of subjects: 520
Study 18945928 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily insulin detemir
Number of subjects: 520
Study 18833102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolperisone
Number of subjects: 360
Study 18833102 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 360
Study 18833102 — intervention group
Group type: EXPERIMENTAL
Intervention: Other muscle relaxants
Number of subjects: 360
Study 16014056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg
Number of subjects: 82
Study 16014056 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of pravastatin
Number of subjects: 82
Study 16014056 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous statin use
Number of subjects: 82
Study 16014056 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin treatment
Number of subjects: 82
Study 16014056 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial statin treatment
Number of subjects: 82
Study 11825820 — intervention group
Group type: EXPERIMENTAL
Intervention: Phacoemulsification in group A (operating time 30 minutes or less)
Number of subjects: 34
Study 11825820 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracapsular cataract extraction (ECCE) in group B (operating time greater than 30 minutes)
Number of subjects: 34
Study 11825820 — intervention group
Group type: EXPERIMENTAL
Intervention: Final refraction in group A
Number of subjects: 34
Study 11825820 — intervention group
Group type: COMPARATOR
Intervention: Final refraction in group B
Number of subjects: 34
Study 11825820 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between final refraction and duration of surgery
Number of subjects: 34
Study 11825820 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic retinopathy in group A
Number of subjects: 34
Study 10365834 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/0 polydioxanone (PDS) suture material (n = 103)
Number of subjects: 220
Study 10365834 — intervention group
Group type: COMPARATOR
Intervention: 2/0 polypropylene (Prolene) suture material (n = 98)
Number of subjects: 220
Study 7497718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine (group 1: mean 22 +/- 15 micrograms/kg/min; group 2: mean 57 +/- 41 micrograms/kg/min)
Number of subjects: 25
Study 7497718 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine
Number of subjects: 25
Study 1724273 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonnecor
Number of subjects: 68
Study 1724273 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacizine
Number of subjects: 68
Study 1724273 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 68
Study 7138748 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAID), given three times daily for a week.
Number of subjects: 36
Study 7138748 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID treatment (specific drugs not detailed), randomized order of administration.
Number of subjects: 36
Study 31488429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract (70% of blindness cases)
Number of subjects: 3120
Study 31488429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract blindness
Number of subjects: 3120
Study 31488429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgical coverage
Number of subjects: 3120
Study 31800960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical cyclosporine A (CsA) 0.05% for 4 weeks
Number of subjects: 18
Study 31800960 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diquafosol tetrasodium (DQS) 3% for 4 weeks
Number of subjects: 18
Study 27885751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillation (CRT-D)
Number of subjects: 903
Study 27885751 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy with Defibrillation (CRT-D) in prolonged baseline PR interval subgroup
Number of subjects: 903
Study 27885751 — intervention group
Group type: COMPARATOR
Intervention: Optimal Pharmacologic Therapy (OPT)
Number of subjects: 903
Study 26466804 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-based telephone follow-up
Number of subjects: 440
Study 26466804 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 440
Study 23665752 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition with both target and control cursor visible
Number of subjects: 0
Study 23665752 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition where a cue was added
Number of subjects: 0
Study 23665752 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition where a cue was removed
Number of subjects: 0
Study 23665752 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition where a new cue was used after the old one was removed
Number of subjects: 0
Study 22190528 — intervention group
Group type: EXPERIMENTAL
Intervention: Compound anisodine injection (CA group)
Number of subjects: 46
Study 22190528 — intervention group
Group type: COMPARATOR
Intervention: Venoruton tablets (control group)
Number of subjects: 46
Study 19644045 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (320/9 microg) plus tiotropium (18 microg once daily)
Number of subjects: 660
Study 19644045 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium alone
Number of subjects: 660
Study 17656453 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct likelihood analysis
Number of subjects: 0
Study 17656453 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0
Study 17656453 — intervention group
Group type: EXPERIMENTAL
Intervention: Generalized estimating equations
Number of subjects: 0
Study 17656453 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible models for outcome and missingness processes
Number of subjects: 0
Study 15554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Number of subjects: 132
Study 15554570 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 132
Study 15554570 — intervention group
Group type: COMPARATOR
Intervention: Usual care plus a self-help booklet (BUC)
Number of subjects: 132
Study 11430175 — intervention group
Group type: EXPERIMENTAL
Intervention: SSRIs (selective serotonin reuptake inhibitors) as first-line treatment for depressive and anxiety disorders
Number of subjects: 0
Study 11430175 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer antidepressants (venlafaxine, bupropion, nefazodone, mirtazapine)
Number of subjects: 0
Study 9734297 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete stimulus omission
Number of subjects: 0
Study 9734297 — intervention group
Group type: EXPERIMENTAL
Intervention: Variation of a previously constant ISI
Number of subjects: 0
Study 9734297 — intervention group
Group type: EXPERIMENTAL
Intervention: Short ISIs (0.5-1.5 s)
Number of subjects: 0
Study 7932276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (2,500 lux) between 0600 and 0800 hours
Number of subjects: 24
Study 7932276 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light treatment (2,500 lux)
Number of subjects: 24